Company Name, Ticker, Competitors, else..

Portage Biotech Inc (NASDAQ: PRTG)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Portage Biotech Inc 's

Name: Portage Biotech Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PRTG Sales vs. its Competitors Q4 2025

Comparing the current results to its competitors, Portage Biotech Inc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 3.47 %, recorded in the same quarter.

• List of PRTG Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Portage Biotech Inc , slower than the average decrease reported by the company's competitors of -5.86 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -5.86 %

<< PRTG Stock Performance Comparisons

Portage Biotech Inc 's Comment on Competition and Industry Peers

The market for PD-1 antibodies includes at least 14 approved products, with participation from every major pharmaceutical company. Extending the applications of PD-1 antibodies presents potential opportunities for companies seeking to increase market share. The company competes with established large pharmaceutical firms in the pharmaceutical and biotherapeutic development sectors.

<< See the full list of PRTG competitors

*Market share is calculated based on total revenue.

PRTG's Stock Performance relative to its Competitors

Publicly Traded Peers of Portage Biotech Inc

Zymeworks Inc
Share Performance

-4.42%

Over The Past 5 Days

Zymeworks Inc

Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,051.842 mill.	$ 37.127 mill.	$ -149.992 mill.

Nextcure Inc
Share Performance

+31.77%

Over The Past 5 Days

Nextcure Inc

Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 44.708 mill.	$ - mill.	$ -42.748 mill.

Nuvalent Inc
Share Performance

+0.05%

Over The Past 5 Days

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

Intellia Therapeutics Inc
Share Performance

+5.74%

30 Days

Intellia Therapeutics Inc

Profile

Intellia Therapeutics Inc is a biotechnology company focused on developing therapies based on CRISPR/Cas9 gene editing technology.

More about Intellia Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,696.531 mill.	$ 59.506 mill.	$ -399.975 mill.

Nurix Therapeutics Inc
Share Performance

+71.01%

This Quarter

Nurix Therapeutics Inc

Profile

Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.

More about Nurix Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,902.636 mill.	$ 36.766 mill.	$ -341.351 mill.

49 more competitors available

Sources: Portage Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 10:06 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Portage Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.